Comparison of NNRTIs in antiretroviral-experienced patients

Powderly WG . The strategy of antiretroviral switch studies—a review. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 2000. Abstract 1375

Maggiolo F , Migliorino M , Pravettoni G , Rizzi M , Capriolo S , Suter F . Management of Pi-associated metabolic changes by substitution with efavirenz in virologically controlled HIV+ persons. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 2000. Abstract 1533

Bickel M , Rickerts V , Klauke S The Protra Study: switch from PI to abacavir (ABC) and efavirenz (EFV) in HIV-1 infected adults previously treated with 2 NRTIs and a PI with undetectable HIV-RNA levels (vRNA). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 2000. Abstract 1531

Lafon E , Bani Sadr F , Chandemerle C LIPSTOP Study: evolution of clinical lipodystrophy (LD), blood lipids, visceral (VAT) and subcutaneous (SAT) adipose tissue after switching from protease inhibitor (PI) to efavirenz (EFV) in HIV-1 infected patients. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 2000. Abstract 1535

Knechten H , Stümer KH , Höhn C , Braun P . 24 week follow-up of patients switching from a protease inhibitor (PI) containing regimen with lamivudine (3TC) and stavudine (d4T) or zidovudine (AZT) to an efavirenz (EFV) based therapy. 40th Inter science Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 2000. Abstract 1532

Katlama C , Staszewski S , Clumeck N Successful substitution of protease inhibitors with efavirenz in patients with undetectable plasma HIV-1 RNA levels: 48-week results of a prospective, randomized, multicenter, open-label study (DMP 266-027). 11th European Congress of Clinical Microbiology and Infectious Diseases. Istanbul, Turkey, April 2001. Abstract 044

Becker S , Rachlis A , Gill J Successful substitution of protease inhibitors with efavirenz in patients with undetectable plasma HIV-1 RNA levels: results of a prospective, randomized, multicenter, open-label study (DMP 266-049). 8th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, February 2001. Abstract 20

De Luca A , Baldini F , Cingolani A Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study. AIDS 2000;14:16556

Barreiro P , Soriano V , Blanco F , Casimiro C , de la Cruz JJ , González-Lahoz J . Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000;14:80712

Ruiz L , Negredo E , Domingo P Clinical, virological and immunological benefit of switching the protease inhibitor (PI) by nevirapine (NVP) in HAART-experienced patients suffering lipodystrophy (LD): 36-week follow-up. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, January-February 2000. Abstract 206

Negredo E , Cruz L , Ruiz L Impact of switching from protease inhibitors (PI) to nevirapine (NVP) or efavirenz (EFV) in patients with viral suppression. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 2000. Abstract 473

British HIV Association (BHIVA) Guidelines for the Treatment of HIV. New BHIVA Guidelines. Issued December 1999. [http://www.aidsmap.com/bhiva/bhivagdl299.htm (accessed 14 December 2000)]

Gulick RM Salvage therapy with saquinavir in combination with ritonavir or nelfinavir plus delavirdine, adefovir, or both—ACTG 359. 3rd International Workshop on Salvage Therapy in HIV Infection. Chicago, USA, April 2000. Abstract 19. Report and Abstracts in Antivir Ther 2000;5(Suppl 2):viixii, 1-35

Moyle GJ , Wilkins E , Leen C , Cheesbrough A , Reynolds B , Gazzard BG . Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use. AIDS 2000;14: 14534

Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, [http://www.hivatis.org/guidelines/adult/pdf/AdulttotalFeb04shaded.pdf (accessed 5 February 2001)]

Khanna N , Klimkait T , Schiffer V Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor or heavily pre-treated HIV-1 infected patients. Swiss HIV cohort study. AIDS 2000;14:7919

Rockstroh J , Brun S , Bertz R Kaletra (ABT-378/ritonavir) and efavirenz: 48-week safety/efficacy evaluation in multiple PI-experienced patients. 5th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, October 2000. Abstract P43